Sepragen.com

Home | Contact Us 


Online Catalog


View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at sales@sepragen.com.



How Can We Help You?
Click here to contact us!

 



Sepragen Announces Increased Bookings

San Leandro, CA, January 15, 2001 -- Sepragen Corporation (OTC BB: SPGNA), a provider of patented technology and equipment for purification needs in the nutritional and biotech industries, today announced an increase in bookings for the fourth quarter of 2000. Bookings totaled over $600,000 which are the highest in the last two years.

Dr. "Skip" Edmunds, Sepragen's acting CFO, commenting on this increase, said, "Sepragen's technology is revolutionary and the price points of the larger systems require missionary sales and service effort which can only be obtained by a direct customer contact." Dr. Edmunds continued, "While one data point does not make a trend, we are optimistic that this strategy is sound and is starting to have an impact." Sepragen had previously announced a switch from third-party distributors to a direct sales organization in the domestic biotech market.

Sepragen is a leading supplier of separation process technology, equipment and consumables to the biotechnology and nutraceutical industries. In addition to its biotech drug separation business, the Company has developed patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy as well as extracting proteins from whey. The Company holds over 14 issued patents relating to its core technology.

Return to News Archives main page



The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.


Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2018 Sepragen Corporation. All rights reserved. (510) 475-0650